Evidence map›Paper›PMID 40384328›Full record

Trial reportInfluenza and other respiratory viruses2025

Pharmacodynamic Effect of Different Dosage Regimes of Oseltamivir in Severe Influenza Patients Requiring Mechanical Ventilation: A Multicentre Randomised Controlled Trial.

Wai-Tat Wong, Gordon Choi, Xiansong Wang, William Ka Kei Wu, Ge Lin, Martin Chi Wai Chan, King Chung Kenny Chan, Philip Koon Ngai Lam, David Shu Cheong Hui, Matthew T V Chan

Abstract readRandomized Controlled TrialMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Influenza and other respiratory viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Wai-Tat WongDepartment of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Hong Kong SAR, China.ORCID 0000-0002-7228-9486
Gordon ChoiDepartment of Anaesthesia and Intensive Care, Prince of Wales Hospital, Hong Kong SAR, China.
Xiansong WangDepartment of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Hong Kong SAR, China.
William Ka Kei WuDepartment of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Hong Kong SAR, China.
Ge LinSchool of Biomedical Sciences, The Chinese University of Hong Kong, Hong Kong SAR, China.
Martin Chi Wai ChanDepartment of Microbiology, The Chinese University of Hong Kong, Hong Kong SAR, China.
King Chung Kenny ChanDepartment of Intensive Care, Tuen Mun Hospital, Hong Kong SAR, China.
Philip Koon Ngai LamDepartment of Intensive Care, North District Hospital, Hong Kong SAR, China.
David Shu Cheong HuiDepartment of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong SAR, China.
Matthew T V ChanDepartment of Anaesthesia and Intensive Care, The Chinese University of Hong Kong, Hong Kong SAR, China.

Funding

Health and Medical Research Fund (HMRF) Commissioned Research on Control of Infectious Diseases (Phase III) CU-15-A13
6 · The paper itself

Abstract

BACKGROUND AND

objectivesThis randomised controlled trial evaluated whether higher doses of oseltamivir would improve virological and clinical outcomes in severe influenza patients requiring invasive mechanical ventilation.

methodsForty intubated adult patients with severe influenza A or B from four intensive care units in Hong Kong were enrolled and randomised to receive either a double dose (300 mg/day) or a triple dose (450 mg/day) of oseltamivir for 10 days. Baseline data were collected, and outcomes were assessed daily using SOFA and Murray scores. Viral RNA was quantified from nasopharyngeal and tracheal aspirates. The primary outcome was the viral clearance rate after 5 days of treatment; secondary outcomes included 28-day and hospital mortality rates, changes in viral load, and serial SOFA and Murray scores.

resultsViral clearance rates after 5 days of treatment were low and similar between the double (3/20, 15%) and triple-dose groups (2/20, 10%). No significant differences were observed in 28-day mortality, hospital mortality, ICU length of stay or duration of mechanical ventilation between the double and triple-dose groups. However, patients receiving triple doses exhibited a faster decline in influenza A viral load but had a longer hospital length of stay.

conclusionsTriple doses of oseltamivir did not significantly improve virological or clinical outcomes compared with double doses in severe influenza.

Indexed as

Antiviral AgentsInfluenza, HumanOseltamivirRespiration, ArtificialAdultAgedFemaleHong KongHumansInfluenza A virusInfluenza B virusIntensive Care UnitsMaleMiddle AgedTreatment OutcomeViral LoadAntiviral AgentsOseltamivirmechanical ventilationoseltamivirsevere influenza

Identifiers

PMID40384328
PMCPMC12086322

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.